HIV Mutation Detail Information

Virus Mutation HIV Mutation I51A-S52A


Basic Characteristics of Mutations
Mutation Site I51A-S52A
Mutation Site Sentence In addition, we included double mutants P49A–K50A and I51–S52A, because of their proximity to other double mutants that showed significant defects in CBFβ binding.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region Vif
Standardized Encoding Gene Vif  
Genotype/Subtype HIV-1
Viral Reference -
Functional Impact and Mechanisms
Disease HIV Infections    
Immune -
Target Gene CBFB   
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location -
Literature Information
PMID 28302150
Title Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFbeta that is critical for Vif function
Author Desimmie BA,Smith JL,Matsuo H,Hu WS,Pathak VK
Journal Retrovirology
Journal Info 2017 Mar 17;14(1):19
Abstract BACKGROUND: HIV-1 Vif interacts with the cellular core-binding factor beta (CBFbeta) and counteracts the protective roles of certain human APOBEC3 (A3) proteins by targeting them for proteasomal degradation. Previous studies have identified some amino acids important for Vif-CBFbeta interactions, and recently a co-crystal structure of a pentameric complex of HIV-1 Vif, CBFbeta, Cul5, EloB, and EloC was resolved. However, a comprehensive analysis of Vif-CBFbeta interactions that are important for Vif function has not been performed. RESULTS: Here, we carried out double-alanine scanning mutagenesis of the first 60 amino acids of Vif and determined their effects on interaction with CBFbeta and their ability to induce A3G degradation as well as rescue HIV-1 replication in the presence of A3G. We found that multiple Vif residues are involved in the extensive N-terminal Vif-CBFbeta interaction and that the (5)WQVMIVW(11) region of Vif is the major determinant. A minimum of three alanine substitutions are required to completely abrogate the Vif-CBFbeta interaction and Vif's ability to rescue HIV-1 infectivity in the presence of A3G. Mutational analysis of CBFbeta revealed that F68 and I55 residues are important and participate in a tripartite hydrophobic interaction with W5 of Vif to maintain a stable and functional Vif-CBFbeta complex. We also determined that CBFbeta amino acids (73)WQGEQR(78), which are not resolved in the structure of the pentameric complex, are not involved in interaction with HIV-1 Vif. CONCLUSIONS: Our results provide detailed insight into the Vif-CBFbeta interactions that are critical for Vif function and may contribute to the rational design of HIV-1 inhibitors that block Vif-mediated degradation of A3 proteins.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.